^
Association details:
| Biomarker: | PIK3CA mutation + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug Class: | CDK4 inhibitor + CDK6 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
256P - PI3K mutation is associated with reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer
Published date:
09/13/2021
Excerpt:
The present study evaluated the incidence and distribution of de novo PIK3CA mutations in hormone receptor-positive / HER2-negative metastatic breast cancer (MBC) and its impact on clinical outcomes of patients treated with CDK4/6 inhibitors….PIK3CA mutation was associated with shorter progression-free survival (PFS) compared to PIK3CA wild type (18 versus 32.2 months, p-value 0.004)...
